Review of Treatments for ADPKD on Tolvaptan and ketogenic Dietary Intervention as a Novel Therapy

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), the most prevalent genetic kidney disease, affected millions of individuals worldwide. And it is also one of the most prevalent causes of kidney failures and transplants. Previously, in many years, mitigating its symptoms had been the only treatment for this disease. After more than a decade after the early clinical studies of medicines for ADPKD began, the first medication that may successfully delay the course of the condition is now on the market. Due to the severe side effects and high cost of tolvaptan, it cannot be considered a full success, but rather the beginning of therapeutic research. More recently, enlightened by the discovery of the defective metabolism of PKD related cells, researchers have been designing dietary plans and new lifestyles for ADPKD patients to slow down or even halt the disease progression. Current outcomes have been promising. This article will address the best practices for treating ADPKD patients, with a focus on medications that have been proved to be beneficial in preserving kidneys function and structure.